<code id='3890DBED86'></code><style id='3890DBED86'></style>
    • <acronym id='3890DBED86'></acronym>
      <center id='3890DBED86'><center id='3890DBED86'><tfoot id='3890DBED86'></tfoot></center><abbr id='3890DBED86'><dir id='3890DBED86'><tfoot id='3890DBED86'></tfoot><noframes id='3890DBED86'>

    • <optgroup id='3890DBED86'><strike id='3890DBED86'><sup id='3890DBED86'></sup></strike><code id='3890DBED86'></code></optgroup>
        1. <b id='3890DBED86'><label id='3890DBED86'><select id='3890DBED86'><dt id='3890DBED86'><span id='3890DBED86'></span></dt></select></label></b><u id='3890DBED86'></u>
          <i id='3890DBED86'><strike id='3890DBED86'><tt id='3890DBED86'><pre id='3890DBED86'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:128
          Two researchers look at a computer monitor showing a graph and other data
          Adobe

          Research universities are voicing concerns over some proposed changes to the process for reviewing scientific misconduct allegations, citing worries that new government requirements would hobble their own independent procedures and constitute a huge administrative burden.

          Nearly two decades since it last released research misconduct rules, the U.S. Office of Research Integrity (ORI) is ready to update its requirements for ensuring the scientific standards of projects funded by the U.S. Department of Health and Human Services, including the National Institutes of Health.

          advertisement

          The proposed changes, published on Oct. 6, include a new formal process that institutions would follow in reviewing allegations, a 30-day deadline for institutions to assess allegations, and provisions that make it harder to quickly dismiss cases that institutions believe to be “honest errors.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Why the world’s most expensive drug might be worth the price
          Why the world’s most expensive drug might be worth the price

          AdobeThestaffoftheInstituteforClinicalandEconomicReview,orICER,areknownasthenerdsofthedrugindustry:b

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          The biotech scorecard for Q4: 16 stock

          RyanPierse/GettyImagesHereisSTAT’sbiotechscorecard,ourregularledgerofstock-movingbiotechevents,forth